Here we sought to investigate the prevalence and co-alteration landscape of genomic alterations in non-Sq NSCLC using a diverse real-world cohort comprising patients of European (EUR), African (AFR), East Asian (EAS), South Asian (SAS), and Admixed American (AMR) ancestries, focusing our analyses on tumors with alterations in KRAS and EGFR, the two major oncogenic drivers of non-Sq NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.